Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice

CRISPR/Cas9-mediated beta-globin (HBB) gene correction of sickle cell disease (SCD) patient-derived hematopoietic stem cells (HSCs) in combination with autologous transplantation represents a recent paradigm in gene therapy. Although several Cas9-based HBB-correction approaches have been proposed, f...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkinson, Adam C., Dever, Daniel P., Baik, Ron, Camarena, Joab, Hsu, Ian, Charlesworth, Carsten T., Morita, Chika, Nakauchi, Hiromitsu, Porteus, Matthew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846836/
https://www.ncbi.nlm.nih.gov/pubmed/33514718
http://dx.doi.org/10.1038/s41467-021-20909-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846836/
https://www.ncbi.nlm.nih.gov/pubmed/33514718
http://dx.doi.org/10.1038/s41467-021-20909-x

Ejemplares similares